Portfolio News
Sofinnova Industrial Biotech
Danish biotech specialist raises €20 million to accelerate market-ready trait development
Danish biotechnology company Traitomic has raised €20 million in a Series A round led by Sofinnova Partners. The investor consortium also includes the Export and Investment Fund of Denmark (EIFO), Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures. The round marks Traitomic's first external investment since its spin-out from Carlsberg and follows the development of a growing customer base across multiple industries. The funding will support international expansion and continued development of the company's scientific and commercial capabilities.
The world increasingly depends on improved biological performance to address challenges in food security, resource efficiency and sustainability. Yet translating a biological need into a commercially relevant trait can be slow, fragmented and difficult to scale. Traitomic helps bridge that gap not only by developing market-ready traits, but also supporting customers from initial commercial challenges through to deployment.
(L-R) Toni Wendt, Technology Lead; Jan Gottlieb, Commercial Lead; Gustav Hambraeus, Managing Director
Traitomic's proprietary FIND-IT platform identifies specific genetic variants in conventionally bred populations without gene editing, enabling rapid trait development while maintaining broad regulatory and commercial applicability. Unlike many trait-development approaches that are tailored to specific organism types, the platform can be applied across both plant and microbial systems.
To date, Traitomic has delivered 116 traits to 47 customers across 32 organisms spanning plant breeding and seed; food supply chain and precision nutrition; and biosolutions and industrial biotech. The projects range from improving crop robustness and yield, to developing differentiated food products with enhanced flavour, nutrition or shelf life, and optimising enzymes and strains used in industrial biotechnology. This breadth of applications reflects demand from customers across multiple industries and highlights the significant opportunity to expand trait development across the broader bioeconomy.
The funding will support Traitomic's international expansion and help the company capture this opportunity across food, agriculture and biosolutions markets. In addition, Traitomic will continue to broaden its integrated offering, enabling closer collaboration with customers from initial biological or commercial challenges through delivery of market-ready traits.
Gustav Hambraeus, CEO and co-founder, Traitomic said: "This investment marks the beginning of Traitomic's next chapter. Over the past years, we have demonstrated that customers across the food value chain are looking for faster routes from biological insight to commercial impact. With the support of our new investors, we can now expand internationally, deepen our collaboration with customers and bring our integrated approach to trait development to many more innovation challenges."
Michael Krel, Partner, Sofinnova Partners said: "Traitomic has demonstrated something that is rare in biological innovation: the ability to develop commercially relevant traits across a broad range of organisms and applications. Combined with the company's strong customer traction and proven track record, this creates a compelling foundation for future growth. We believe Traitomic is well positioned to become a leading partner for trait development across agriculture, food and industrial biotechnology, and we look forward to supporting the team with both capital and experience as they enter their next phase of international expansion."
Anders Røed, Executive Vice President, Group Strategy and Commercial, Carlsberg said: "Traitomic is an excellent example of how fundamental research can create value far beyond its original field of application. FIND-IT was developed at Carlsberg Research Laboratory to improve barley, and it is now enabling advances in agriculture, food production and industrial biotechnology. I am proud of what the team has achieved and excited to continue supporting the company as it enters this next phase of international growth."
For more information:
Traitomic
Email: hello@traitomic.com
Tel: +45 22 51 52 62
traitomic.com/
Publication date: Tue 17 Nov 2026
Related News
Mironid strengthens Board and clinical team to support next phase of growth
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Biotalys Achieves Critical Manufacturing Milestone for First Commercial Biofungicide EVOCA® NG
Polish AI Start-up Claims First Place on LongevityBench and Open-Sources a Version of its Thalamus Reasoning Model
Tenpoint Therapeutics Launches the YUVEZZI™ Telehealth Prescribing Program